Katelyn E McCabe1, Bin Liu, James D Marks, James S Tomlinson, Hong Wu, Anna M Wu. 1. Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA. kmccabe@ucla.edu
Abstract
PURPOSE: The purpose of this study was to generate and evaluate a positron emission tomography (PET) radiotracer targeting activated leukocyte cell adhesion molecule (ALCAM). PROCEDURES: A human anti-ALCAM single chain variable fragment was reformatted to produce a covalent dimer, termed a cys-diabody (CysDb). Purified CysDb was characterized by gel electrophoresis and size exclusion chromatography, and immunoreactivity was assessed by flow cytometry and immunofluorescence. Targeting and imaging of ALCAM-positive tumors using (64)Cu-DOTA-CysDb were evaluated in mice bearing human pancreatic adenocarcinoma xenografts (HPAF-II or BxPC-3). RESULTS: CysDb binds specifically to ALCAM-positive cells in vitro with an apparent affinity in the range of 1-3 nM. MicroPET images at 4 h showed specific targeting of positive tumors in vivo, a finding confirmed by biodistribution analysis, with positive/negative tumor ratios of 1.9 ± 0.6 and 2.4 ± 0.6, and positive tumor/blood ratios of 2.5 ± 0.9 and 2.9 ± 0.6 (HPAF-II and BxPC-3, respectively). CONCLUSIONS: Successful imaging with (64)Cu-DOTA-CysDb in animal models suggests further investigation of ALCAM as an imaging biomarker is warranted.
PURPOSE: The purpose of this study was to generate and evaluate a positron emission tomography (PET) radiotracer targeting activated leukocyte cell adhesion molecule (ALCAM). PROCEDURES: A human anti-ALCAM single chain variable fragment was reformatted to produce a covalent dimer, termed a cys-diabody (CysDb). Purified CysDb was characterized by gel electrophoresis and size exclusion chromatography, and immunoreactivity was assessed by flow cytometry and immunofluorescence. Targeting and imaging of ALCAM-positive tumors using (64)Cu-DOTA-CysDb were evaluated in mice bearing humanpancreatic adenocarcinoma xenografts (HPAF-II or BxPC-3). RESULTS:CysDb binds specifically to ALCAM-positive cells in vitro with an apparent affinity in the range of 1-3 nM. MicroPET images at 4 h showed specific targeting of positive tumors in vivo, a finding confirmed by biodistribution analysis, with positive/negative tumor ratios of 1.9 ± 0.6 and 2.4 ± 0.6, and positive tumor/blood ratios of 2.5 ± 0.9 and 2.9 ± 0.6 (HPAF-II and BxPC-3, respectively). CONCLUSIONS: Successful imaging with (64)Cu-DOTA-CysDb in animal models suggests further investigation of ALCAM as an imaging biomarker is warranted.
Authors: Jeffrey V Leyton; Tove Olafsen; Mark A Sherman; Karl B Bauer; Patrick Aghajanian; Robert E Reiter; Anna M Wu Journal: Protein Eng Des Sel Date: 2008-10-28 Impact factor: 1.650
Authors: Sara Ahlgren; Helena Wållberg; Thuy A Tran; Charles Widström; Magnus Hjertman; Lars Abrahmsén; Dietmar Berndorff; Ludger M Dinkelborg; John E Cyr; Joachim Feldwisch; Anna Orlova; Vladimir Tolmachev Journal: J Nucl Med Date: 2009-04-16 Impact factor: 10.057
Authors: Douglas W Schneider; Tara Heitner; Bruno Alicke; David R Light; Kirk McLean; Noboru Satozawa; Gordon Parry; Jeongsoo Yoo; Jason S Lewis; Renate Parry Journal: J Nucl Med Date: 2009-02-17 Impact factor: 10.057
Authors: Sven H Hausner; Craig K Abbey; Richard J Bold; M Karen Gagnon; Jan Marik; John F Marshall; Cathy E Stanecki; Julie L Sutcliffe Journal: Cancer Res Date: 2009-06-23 Impact factor: 12.701
Authors: Laura A Strickland; Jed Ross; Simon Williams; Sarajane Ross; Maria Romero; Susan Spencer; Rich Erickson; Julie Sutcliffe; Caroline Verbeke; Paul Polakis; Nicholas van Bruggen; Hartmut Koeppen Journal: J Pathol Date: 2009-07 Impact factor: 7.996
Authors: Keyu Li; Kirstin A Zettlitz; Julia Lipianskaya; Yu Zhou; James D Marks; Parag Mallick; Robert E Reiter; Anna M Wu Journal: Protein Eng Des Sel Date: 2015-05-19 Impact factor: 1.650
Authors: Keyu Li; Richard Tavaré; Kirstin A Zettlitz; Shannon M Mumenthaler; Parag Mallick; Yu Zhou; James D Marks; Anna M Wu Journal: Mol Cancer Ther Date: 2014-08-20 Impact factor: 6.261
Authors: Richard Tavaré; Wei H Wu; Kirstin A Zettlitz; Felix B Salazar; Katelyn E McCabe; James D Marks; Anna M Wu Journal: Protein Eng Des Sel Date: 2014-08-04 Impact factor: 1.650
Authors: Willemieke S Tummers; Juergen K Willmann; Bert A Bonsing; Alexander L Vahrmeijer; Sanjiv S Gambhir; Rutger-Jan Swijnenburg Journal: Pancreas Date: 2018-07 Impact factor: 3.327